ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Total Other Income
ABL Bio Inc
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Other Income
₩249.6m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Other Income
-₩3.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Other Income
-₩4.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Other Income
-₩3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Other Income
-₩427.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Other Income
₩232.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
36%
|
CAGR 10-Years
28%
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Total Other Income?
Total Other Income
249.6m
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's Total Other Income amounts to 249.6m KRW.
What is ABL Bio Inc's Total Other Income growth rate?
Total Other Income CAGR 3Y
-40%
The average annual Total Other Income growth rates for ABL Bio Inc have been -40% over the past three years .
You don't have any saved screeners yet